Shareholder Abingworth Llp Decreased Cymabay (CBAY) Stake

Marco Green
April 21, 2018

About 477,654 shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 352.38% since April 20, 2017 and is uptrending. It has underperformed by 4.26% the S&P500.

CymaBay Therapeutics Inc (NASDAQ:CBAY) released its quarterly earnings results on Thursday. (NASDAQ:SGMO) for 2.40 million shares. H.C. Wainwright downgraded the shares of CBAY in report on Wednesday, June 1 to "Neutral" rating. (NASDAQ:CBAY)'s earnings report, as reported by RTT. Piper Jaffray maintained CymaBay Therapeutics, Inc. The stock increased 0.83% or $0.11 during the last trading session, reaching $13.43. 16 are the (NASDAQ:CBAY)'s ratings reports on April 19, 2018 according to StockzIntelligence Inc. CBAY outperformed the S&P500 by 186.22%.

Investors sentiment decreased to 0.87 in Q4 2017.

Looking about the past performance history, the company jumped 1.76% for the last five trades and expanded 0.91% in one month period. It dropped, as 16 investors sold Sangamo Therapeutics, Inc. shares while 42 reduced holdings. 58 funds opened positions while 99 raised stakes. Wedbush maintained the shares of SGMO in report on Wednesday, September 2 with "Buy" rating. Moreover, Tocqueville Asset L P has 0.12% invested in Sangamo Therapeutics, Inc. Wells Fargo & Mn has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:FOX). Profund Advsrs Llc has 56,673 shares for 0.07% of their portfolio. Teachers Retirement System Of The State Of Kentucky invested 0.02% in Twenty-First Century Fox, Inc. Pnc Fincl Ser Group Inc, Pennsylvania-based fund reported 339,024 shares. Us Bank De holds 0% or 5,000 shares in its portfolio. Following the completion of the sale, the director now owns 90,000 shares in the company, valued at approximately $1,395,900. (NASDAQ:FOX). Riverhead Ltd Liability Corporation has invested 0.02% in Twenty-First Century Fox, Inc.

Analysts await CymaBay Therapeutics, Inc. Analyst established EPS growth expected to grow of 30.60% for this year and EPS growth for next year is likely to attain at -1.10%. OKE's profit will be $263.08 million for 23.37 P/E if the $0.64 EPS becomes a reality. (NASDAQ:CBAY) rating on Thursday, March 15. Therefore 50% are positive. AU Optronics had 15 analyst reports since July 30, 2015 according to SRatingsIntel. The company was maintained on Friday, March 16 by SunTrust. On Monday, April 3 the stock rating was maintained by Jefferies with "Hold". The stock has "Hold" rating by Morgan Stanley on Tuesday, August 15. The stock of Sangamo Therapeutics, Inc. The market capitalization of the company is $522.11 Million. The company was upgraded on Tuesday, July 19 by Bank of America. Also, Director Kurt Von Emster sold 138,253 shares of the firm's stock in a transaction that occurred on Monday, January 22nd.

CymaBay Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The firm has a market cap of $759.94, a price-to-earnings ratio of -17.01 and a beta of 2.06. According to the Analysts, the Low Estimate Earnings of the current Quarter is $-1.1 whereas, High Estimate is $-0.78. The companyÂ's product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Looking at the Analyst Recommendations of the stock, 2 Analysts issued a Buy for MoSys, 6 gave Outperform, 0 analysts gave Hold Rating, 0 issued Underperform and 0 marked the stock as Sell. Therefore 100% are positive. Cymabay Therapeutics Inc had 30 analyst reports since July 21, 2015 according to SRatingsIntel. (NASDAQ:CBAY) earned "Buy" rating by Leerink Swann. On Wednesday, January 10 the rating was maintained by Oppenheimer with "Buy". H.C. Wainwright maintained the stock with "Neutral" rating in Wednesday, January 4 report. On Wednesday, January 24 the firm has "Buy" rating given by H.C. Wainwright. As per Tuesday, November 28, the company rating was maintained by Leerink Swann. (NYSE:AUO) has "Underperform" rating given on Friday, March 3 by Bernstein. Cantor Fitzgerald restated a "buy" rating and issued a $16.00 price objective on shares of CymaBay Therapeutics in a research note on Friday, March 16th. On Thursday, March 15 the firm has "Buy" rating by Piper Jaffray given.

Other reports by Click Lancashire

Discuss This Article